Titan Pharma Stock Remains Primed to Spike

Titan Pharmaceuticals (TTNP.PK) was mentioned in a weekend article by the Washington Post that highlighted the CEO of Vanda Pharmaceuticals, Mihael Polymeropoulos, and Fanapt - Vanda's recently approved drug to treat schizophrenia of which Titan will reap up to 10% in royalties.

While Novartis (NVS) emerged as Vanda's partner to commercialize the product, it's long been my speculation that Titan will eventually be gobbled up by a larger company, and the following comment by Titan CEO Sunil Bhonsle in the Post article does nothing to stave off my speculation: "There tends to be a pattern where smaller companies do a lot of the innovation, then the larger companies acquire them at a certain point," he said.